Molbio Diagnostics strikes landmark deal with Niramai Health Analytix

INDIA – Molbio Diagnostics has signed a collaboration agreement with Niramai Health Analytix, a Bangalore-based deep-tech startup.

The main objective of the agreement is based on the collaboration of both parties in order to accelerate the adoption of Niramai’s Thermalytix in developing countries around the world.

Through the new agreement, Molbio Diagnostics will promote and distribute Thermalytix in both public and private healthcare markets globally.

It is worth highlighting that Molbio Diagnostics has recently joined hands with CrisprBits to launch innovative CRISPR-based Point-of-Care (POC) tests.

Additionally, Molbio Diagnostics teamed up with SigTuple, a MedTech startup in the field of artificial intelligence (AI) for diagnostics, to develop and market next-generation POC diagnostic testing devices.

In the company’s formal statement, Sriram Natarajan, Vice President of Sales & Marketing at Molbio Diagnostics, said: “We are thrilled to add another cap to our universal access portfolio of innovative healthcare solutions.”

Molbio Diagnostics has officially forayed into breast cancer screening through the collaboration agreement with Niramai Health Analytix.

Molbio is expected to leverage its large-scale manufacturing capability and well-established sales and marketing network to promote and distribute Niramai’s Thermalytix worldwide.

Niramai’s flagship product, Thermalytix, is a novel breast cancer screening solution which is accurate, portable, and automated.

Thermalytix is an innovative AI-based non-invasive breast cancer screening solution that uses patented machine learning algorithms over thermal images to detect early-stage cancer.

The device uses thermal scanning coupled with smart automated AI-enabled software that can detect early signs of breast cancer, which would not have been identified using conventional techniques.

Another unique feature of Thermalytix is that it enables non-touch screening and is aligned with the privacy needs of patients, thereby overcoming hesitation for breast examination.

Setting it apart from the rest, this imaging method is radiation-free, painless, and suitable to all age groups, even young women with dense breasts.

Niramai’s Thermalytix can play an important role in promoting early detection approaches to reduce breast cancer risk and improve outcomes in oncology.

“Niramai’s AI-based Thermalytix device for breast cancer and Molbio’s Truenat HPV-HR test for cervical cancer will enable point-of-care screening and early detection of the two most deadly cancers of women worldwide, saving millions of lives,” outlined Sriram Natarajan.

Subsequently, Niramai’s Thermalytix will help in bridging the critical gaps for the successful prevention and treatment of breast cancer worldwide, especially in low-resource settings.

The strategic partnership between Molbio and Niramai represents a significant milestone in improving the availability and use of early cancer detection and preventive interventions.

The joint effort will help in bridging the critical gaps for the successful prevention and treatment of breast cancer worldwide, especially in low-resource settings.

Moreover, this collaboration builds on the strengths of the two companies to bring cutting-edge technology that would make high-quality diagnostics accessible to everyone.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.